Planned website maintenance is taking place from 11:00 pm AEDT on Friday 30 October to 6:00 am AEDT on Saturday 31 October 2026. Some pages may be temporarily unavailable. If issues continue outside this time, please contact us.
mFLUSIVA Moderna Australia Pty Ltd
Product name
mFLUSIVA
Sponsor
Accepted date
Feb-2026
Active ingredients
influenza virus haemagglutinin mRNA
Summary of proposed indication
mFLUSIVA is a vaccine proposed for active immunisation for the prevention of influenza disease in individuals 50 years of age and older.
Application type
A (new medicine)
Publication date
Feb-2026